Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Nov 8, 2005

Third quarter 2005: Adjusted EPS up 27.4%, net sales up 11.0% on a comparable basis - First 9 months of 2005: Adjusted EPS up 26.6%, net sales up 11.0% on a comparable basis
Nov 7, 2005

New data show long-term (52 week) use of ALVESCO® (ciclesonide) had a low incidence of oropharyngeal side effects in patients with mild-to-moderate asthma
Oct 20, 2005

EXUBERA® inhaled insulin improves blood sugar levels in adults with type 2 diabetes better than diabetes pills alone
Oct 7, 2005

AMBIEN CR™ now available in the US
Sep 29, 2005

Hearing date set on motion for preliminary injunction in ALLEGRA® (fexofenadine hcl) patent infringement case
Sep 29, 2005

Sanofi-aventis provides relief to hurricane victims
Sep 20, 2005

FDA accepts filed pre-market approval supplement to expand the indication for HYALGAN® (sodium hyaluronate) to include shoulder pain due to osteoarthritis
Sep 15, 2005

INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE® (docetaxel)- BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® (trastuzumab) SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER
Sep 14, 2005

Study Finds Alvesco® (ciclesonide) Did Not Affect HPA-Axis Function in Patients with Moderate-to-Severe Persistent Asthma
Sep 12, 2005

Sanofi-aventis Group enters agreement with Prasco Laboratories to market generic versions of ALLEGRA® (fexofenadine HCl)
Sep 8, 2005

FDA Advisory Committee recommends Approval of EXUBERA® for use in adults with type 1 and type 2 diabetes
Sep 6, 2005

AMBIEN CR™ (zolpidem tartrate extended-release tablets) CIV receives FDA Approval for the treatment of insomnia
Aug 31, 2005

Strong growth in 2005 first half adjusted EPS : up 26.1% at €2.22. Increase in full year adjusted EPS guidance. Positive phase IIb/III results for 6 products
Aug 18, 2005

Taxotere® Significantly Improves Survival Compared with paclitaxel In Women With Advanced Breast Cancer
Aug 15, 2005

The U.S. Food and Drug Administration approves ACTONEL® WITH CALCIUM
Aug 2, 2005

Sanofi-aventis Issues Strong Support for Voluntary “Guiding Principles” on DTC Advertising
Jul 27, 2005

ALLEGRA-D® 24 HOUR (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) EXTENDED RELEASE TABLETS NOW AVAILABLE FOR SEASONAL ALLERGY SUFFERERS
Jul 19, 2005

Strong net sales growth in the first half of 2005: 11.0% on a comparable basis - Further increase in market share in the second quarter
Jun 30, 2005

Sports Legend Tony Gwynn Teams up with Former Baseball Champions to Raise Awareness of Deep-Vein Thrombosis (DVT) in the National Educational Campaign, "DVT Blood Clots: Know The Stats. Know Your Risk.”
Jun 28, 2005

PANEL OF EXPERTS AGREE THAT BONE MINERAL DENSITY IS NO LONGER ENOUGH
Jun 23, 2005

RIMONABANT ACCEPTED FOR FILING BY THE FDA
Jun 14, 2005

Data presented at American Diabetes Association Scientific Sessions support Exubera® Efficacy and Safety Profile in Type 1 and Type 2 Diabetes
Jun 13, 2005

Lantus® Add-on to Oral Monotherapy Therapy Showed Improved Glycemic Control in Type 2 Diabetes Patients Compared to Oral Actos Add-on to Oral Therapy
Jun 13, 2005

Clinical Study Results Demonstrated Greater Flexibility With Mealtime Dosing of Apidra® When Compared to Regular Human Insulin
Jun 13, 2005

DATA PRESENTED AT ADA SHOWED THAT BASAL INSULIN THERAPY WITH LANTUS® ACHIEVED TARGET GLYCEMIC CONTROL IN POORLY CONTROLLED TYPE 2 DIABETES

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.